Optionele productanalyse
Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
DuPont de Nemours, Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $17.6B | |
|---|---|---|
| Revenue (ttm) | 7B | |
| Net income (ttm) | 55M | |
| EPS (ttm) | $0.39 | |
| Shares out | 135M | |
| P/E (trailing) | 356.0x | |
| P/E (forward) | 16.5x | |
| Dividend | $2.40 (1.74%) | |
| Volume | 369,186 | |
| Beta | 1.08 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $12.57B | $13.02B | $6.61B | $6.72B | $6.85B | -14.1% |
| Gross profit | $4.03B | $4.03B | $3.63B | $3.91B | $2.07B | -15.3% |
| Operating income | $1.97B | $1.94B | $900.0M | $1.56B | $513.0M | -28.6% |
| Net income | $6.47B | $5.87B | $423.0M | $703.0M | $-779.0M | — |
| EPS (diluted) | $14.92 | $14.75 | $2.82 | $5.04 | $-5.58 | — |
| EBITDA | $3.08B | $3.08B | $2.05B | $2.75B | $1.16B | -21.7% |
| R&D | $557.0M | $536.0M | $192.0M | $203.0M | $193.0M | -23.3% |
| SG&A | $1.60B | $1.47B | $891.0M | $976.0M | $1.02B | -10.7% |
Recent company headlines from major financial publishers.
In the modal base case, DuPont delivers on guided 2H operational acceleration, achieving $7,166M in FY2026 revenue and adjusted EPS of $7.26, followed by FY2027 revenue of $7,451M and EPS of $7.97. Operating EBIT margins expand steadily from 13.5% in 2026 to 15.0% by 2030 through 80/20 productivity gains. Free cash flow conversion remains near 100%, supporting $250M quarterly share repurchases. Intrinsic fair value converges to $100.11, indicating that trading at $130.00 is significantly stretched.
In the upside scenario, rapid realization of 80/20 restructuring efficiencies and sustained mid-single-digit organic growth in Healthcare & Water Technologies expand operating EBIT margins toward 17.0%, while sequential volume exit acceleration (6% in 2H 2026, 7% in Q4) and disciplined buybacks drive FY2027 EPS growth to 12.0%, supporting intrinsic fair value of 128.56.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.5% | $108 | $110 | $113 | $115 | $118 |
| 9.0% | $102 | $104 | $106 | $108 | $111 |
| 9.5% | $96.9 | $98.4 | $100 | $102 | $104 |
| 10.0% | $92.1 | $93.5 | $94.9 | $96.4 | $98.1 |
| 10.5% | $87.9 | $89.1 | $90.3 | $91.6 | $93.0 |
Upcoming earnings date and setup when available.
De rating die de gepubliceerde researcheditie van elke maand droeg. Een rating vergelijkt de koers op de analysedatum met de fair value; het is geen overzicht van of de inschatting juist bleek.
| Jaar | jan | feb | mrt | apr | mei | jun | jul | aug | sep | okt | nov | dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |